Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [ 18F]fluorodeoxyglucose and neuropsychological testing

Sid Gilman, Robert A. Koeppe, Roderick Little, Hyonggin An, Larry Junck, Bruno Giordani, Carol Persad, Mary Heumann, Kris Wernette

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

We compared the relative utility of neuropsychological testing and positron emission tomography (PET) with [ 18F]fluorodeoxyglucose ([ 18F]FDG) in differentiating Alzheimer's disease (AD) from dementia with Lewy bodies (DLB). We studied 25 patients with AD, 20 with DLB, and 19 normal elderly controls. There was no difference between patient groups for MMSE, confrontational naming, or verbal learning. The DLB group was significantly more impaired than the AD group for verbal fluency, and the AD group was significantly more impaired than the DLB group for verbal delayed recall. The DLB group had greater difficulty than the AD group on a visual discrimination task that does not require motor functioning, but the difference did not reach significance. Family ratings of motor functioning suggested significantly greater impairment in DLB patients than in AD patients. PET studies revealed significantly lower local cerebral metabolic rates for glucose (lCMRglc) for visual cortex (Brodmann areas 17, 18, and 19) in the DLB than the AD group, but no differences for other regions commonly affected in AD, including posterior cingulate, superior parietal lobe, lateral temporal lobe, and the prefrontal region. Motor ratings were significantly correlated with lCMRglc in all areas of cerebral cortex, including Brodmann areas 17, 18, and 19. The results demonstrate a similar profile of cerebral hypometabolism in the two patient groups except in the visual cortex, where the DLB group shows markedly lower lCMRglc than the AD group. Neuropsychological testing also differentiates the groups, and family ratings of motor functioning are as robust as PET in these later stages of the disorders.

Original languageEnglish
JournalExperimental Neurology
Volume191
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2005 Feb 1
Externally publishedYes

Fingerprint

Lewy Bodies
Fluorodeoxyglucose F18
Positron-Emission Tomography
Lewy Body Disease
Alzheimer Disease
Visual Cortex
Glucose
Verbal Learning
Parietal Lobe
Gyrus Cinguli
Temporal Lobe
Cerebral Cortex
Dementia

Keywords

  • [ F]fluorodeoxyglucose
  • Alzheimer's disease
  • Dementia with Lewy bodies
  • Local cerebral metabolic rate for glucose
  • Magnetic resonance imaging
  • Neuropsychological testing
  • Positron emission tomography

ASJC Scopus subject areas

  • Neurology
  • Neuroscience(all)

Cite this

Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [ 18F]fluorodeoxyglucose and neuropsychological testing. / Gilman, Sid; Koeppe, Robert A.; Little, Roderick; An, Hyonggin; Junck, Larry; Giordani, Bruno; Persad, Carol; Heumann, Mary; Wernette, Kris.

In: Experimental Neurology, Vol. 191, No. SUPPL. 1, 01.02.2005.

Research output: Contribution to journalArticle

Gilman, Sid ; Koeppe, Robert A. ; Little, Roderick ; An, Hyonggin ; Junck, Larry ; Giordani, Bruno ; Persad, Carol ; Heumann, Mary ; Wernette, Kris. / Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [ 18F]fluorodeoxyglucose and neuropsychological testing. In: Experimental Neurology. 2005 ; Vol. 191, No. SUPPL. 1.
@article{92857509a69e455491607e79bd530242,
title = "Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [ 18F]fluorodeoxyglucose and neuropsychological testing",
abstract = "We compared the relative utility of neuropsychological testing and positron emission tomography (PET) with [ 18F]fluorodeoxyglucose ([ 18F]FDG) in differentiating Alzheimer's disease (AD) from dementia with Lewy bodies (DLB). We studied 25 patients with AD, 20 with DLB, and 19 normal elderly controls. There was no difference between patient groups for MMSE, confrontational naming, or verbal learning. The DLB group was significantly more impaired than the AD group for verbal fluency, and the AD group was significantly more impaired than the DLB group for verbal delayed recall. The DLB group had greater difficulty than the AD group on a visual discrimination task that does not require motor functioning, but the difference did not reach significance. Family ratings of motor functioning suggested significantly greater impairment in DLB patients than in AD patients. PET studies revealed significantly lower local cerebral metabolic rates for glucose (lCMRglc) for visual cortex (Brodmann areas 17, 18, and 19) in the DLB than the AD group, but no differences for other regions commonly affected in AD, including posterior cingulate, superior parietal lobe, lateral temporal lobe, and the prefrontal region. Motor ratings were significantly correlated with lCMRglc in all areas of cerebral cortex, including Brodmann areas 17, 18, and 19. The results demonstrate a similar profile of cerebral hypometabolism in the two patient groups except in the visual cortex, where the DLB group shows markedly lower lCMRglc than the AD group. Neuropsychological testing also differentiates the groups, and family ratings of motor functioning are as robust as PET in these later stages of the disorders.",
keywords = "[ F]fluorodeoxyglucose, Alzheimer's disease, Dementia with Lewy bodies, Local cerebral metabolic rate for glucose, Magnetic resonance imaging, Neuropsychological testing, Positron emission tomography",
author = "Sid Gilman and Koeppe, {Robert A.} and Roderick Little and Hyonggin An and Larry Junck and Bruno Giordani and Carol Persad and Mary Heumann and Kris Wernette",
year = "2005",
month = "2",
day = "1",
doi = "10.1016/j.expneurol.2004.06.017",
language = "English",
volume = "191",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [ 18F]fluorodeoxyglucose and neuropsychological testing

AU - Gilman, Sid

AU - Koeppe, Robert A.

AU - Little, Roderick

AU - An, Hyonggin

AU - Junck, Larry

AU - Giordani, Bruno

AU - Persad, Carol

AU - Heumann, Mary

AU - Wernette, Kris

PY - 2005/2/1

Y1 - 2005/2/1

N2 - We compared the relative utility of neuropsychological testing and positron emission tomography (PET) with [ 18F]fluorodeoxyglucose ([ 18F]FDG) in differentiating Alzheimer's disease (AD) from dementia with Lewy bodies (DLB). We studied 25 patients with AD, 20 with DLB, and 19 normal elderly controls. There was no difference between patient groups for MMSE, confrontational naming, or verbal learning. The DLB group was significantly more impaired than the AD group for verbal fluency, and the AD group was significantly more impaired than the DLB group for verbal delayed recall. The DLB group had greater difficulty than the AD group on a visual discrimination task that does not require motor functioning, but the difference did not reach significance. Family ratings of motor functioning suggested significantly greater impairment in DLB patients than in AD patients. PET studies revealed significantly lower local cerebral metabolic rates for glucose (lCMRglc) for visual cortex (Brodmann areas 17, 18, and 19) in the DLB than the AD group, but no differences for other regions commonly affected in AD, including posterior cingulate, superior parietal lobe, lateral temporal lobe, and the prefrontal region. Motor ratings were significantly correlated with lCMRglc in all areas of cerebral cortex, including Brodmann areas 17, 18, and 19. The results demonstrate a similar profile of cerebral hypometabolism in the two patient groups except in the visual cortex, where the DLB group shows markedly lower lCMRglc than the AD group. Neuropsychological testing also differentiates the groups, and family ratings of motor functioning are as robust as PET in these later stages of the disorders.

AB - We compared the relative utility of neuropsychological testing and positron emission tomography (PET) with [ 18F]fluorodeoxyglucose ([ 18F]FDG) in differentiating Alzheimer's disease (AD) from dementia with Lewy bodies (DLB). We studied 25 patients with AD, 20 with DLB, and 19 normal elderly controls. There was no difference between patient groups for MMSE, confrontational naming, or verbal learning. The DLB group was significantly more impaired than the AD group for verbal fluency, and the AD group was significantly more impaired than the DLB group for verbal delayed recall. The DLB group had greater difficulty than the AD group on a visual discrimination task that does not require motor functioning, but the difference did not reach significance. Family ratings of motor functioning suggested significantly greater impairment in DLB patients than in AD patients. PET studies revealed significantly lower local cerebral metabolic rates for glucose (lCMRglc) for visual cortex (Brodmann areas 17, 18, and 19) in the DLB than the AD group, but no differences for other regions commonly affected in AD, including posterior cingulate, superior parietal lobe, lateral temporal lobe, and the prefrontal region. Motor ratings were significantly correlated with lCMRglc in all areas of cerebral cortex, including Brodmann areas 17, 18, and 19. The results demonstrate a similar profile of cerebral hypometabolism in the two patient groups except in the visual cortex, where the DLB group shows markedly lower lCMRglc than the AD group. Neuropsychological testing also differentiates the groups, and family ratings of motor functioning are as robust as PET in these later stages of the disorders.

KW - [ F]fluorodeoxyglucose

KW - Alzheimer's disease

KW - Dementia with Lewy bodies

KW - Local cerebral metabolic rate for glucose

KW - Magnetic resonance imaging

KW - Neuropsychological testing

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=11444270025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11444270025&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2004.06.017

DO - 10.1016/j.expneurol.2004.06.017

M3 - Article

C2 - 15629765

AN - SCOPUS:11444270025

VL - 191

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - SUPPL. 1

ER -